MX2007015740A - Modulacion sinergistica de tirosina cinasa 3 tipo fms usando moduladores de tienopirimidina y tienopiridina cinasa. - Google Patents

Modulacion sinergistica de tirosina cinasa 3 tipo fms usando moduladores de tienopirimidina y tienopiridina cinasa.

Info

Publication number
MX2007015740A
MX2007015740A MX2007015740A MX2007015740A MX2007015740A MX 2007015740 A MX2007015740 A MX 2007015740A MX 2007015740 A MX2007015740 A MX 2007015740A MX 2007015740 A MX2007015740 A MX 2007015740A MX 2007015740 A MX2007015740 A MX 2007015740A
Authority
MX
Mexico
Prior art keywords
flt3
kinase
thienopyrimidine
sub
thienopyridine
Prior art date
Application number
MX2007015740A
Other languages
English (en)
Inventor
Michael David Gaul
Christian Andrew Baumann
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MX2007015740A publication Critical patent/MX2007015740A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a un metodo para inhibir actividad o expresion de FLT3 tirosina cinasa o reduccion de actividad o expresion de FLT3 tirosina cinasa en una celula o un sujeto que comprende la administracion de un inhibidor de farnesil transferasa y un inhibidor de FLT3 cinasa seleccionado de compuestos tienopirimidina y tienopiridina de formula I' y formula II': (Ver formulas I' y II') donde R1, R3, B, Z, Q, p, q y X son como se definio anteriormente; incluido dentro de la presente invencion estan ambos metodos profilactico y terapeutico para el tratamiento de un sujeto en riesgo de (o susceptible a) desarrollar un trastorno proliferante o un trastorno relacionado a FLT3.
MX2007015740A 2005-06-10 2006-06-07 Modulacion sinergistica de tirosina cinasa 3 tipo fms usando moduladores de tienopirimidina y tienopiridina cinasa. MX2007015740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68940905P 2005-06-10 2005-06-10
PCT/US2006/022101 WO2006135630A1 (en) 2005-06-10 2006-06-07 Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators

Publications (1)

Publication Number Publication Date
MX2007015740A true MX2007015740A (es) 2008-04-29

Family

ID=37067880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015740A MX2007015740A (es) 2005-06-10 2006-06-07 Modulacion sinergistica de tirosina cinasa 3 tipo fms usando moduladores de tienopirimidina y tienopiridina cinasa.

Country Status (10)

Country Link
US (1) US20060281769A1 (es)
EP (1) EP1893215A1 (es)
JP (1) JP2008543756A (es)
KR (1) KR20080028919A (es)
CN (1) CN101242846A (es)
AU (1) AU2006258040A1 (es)
BR (1) BRPI0611960A2 (es)
CA (1) CA2611680A1 (es)
MX (1) MX2007015740A (es)
WO (1) WO2006135630A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US8859602B2 (en) 2006-04-20 2014-10-14 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2705719C (en) 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2773131C (en) 2009-09-04 2015-07-14 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
ES2608628T3 (es) 2012-08-07 2017-04-12 Janssen Pharmaceutica Nv Procedimiento para la preparacion de derivados de ester heterociclicos
KR20160138136A (ko) * 2014-04-15 2016-12-02 연세대학교 산학협력단 티에노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 백혈병 치료 및 예방용 약학 조성물
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
MX2018011105A (es) 2016-03-16 2018-11-22 Kura Oncology Inc Inhibidores sustituidos de menina-mll y metodos de uso.
CA3015845A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
TW531533B (en) * 1998-12-23 2003-05-11 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives having farnesyl transferase and geranylgeranyl transferase inhibiting activity
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0611960A2 (pt) 2009-01-27
WO2006135630A1 (en) 2006-12-21
US20060281769A1 (en) 2006-12-14
KR20080028919A (ko) 2008-04-02
CN101242846A (zh) 2008-08-13
AU2006258040A1 (en) 2006-12-21
EP1893215A1 (en) 2008-03-05
CA2611680A1 (en) 2006-12-21
JP2008543756A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
MX2007015740A (es) Modulacion sinergistica de tirosina cinasa 3 tipo fms usando moduladores de tienopirimidina y tienopiridina cinasa.
WO2006135636A3 (en) Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
WO2006135713A3 (en) Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor
MX2007015741A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms.
TNSN08278A1 (en) Triazolopyridazines as tyrosine kinase modulators
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
MX2010000617A (es) Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
NO20061194L (no) Mitotiske kinesininbibitorer
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
MX2009002377A (es) Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
MX2021009667A (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
BRPI0611965A2 (pt) modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
MY133403A (en) Tetracycline derivatives and methods of use thereof
BRPI0612000A2 (pt) modulaÇço sinergÍstica de flt3 cinase usando alquilquinolinas e alquilquinazolinas
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MY147226A (en) Method of inhibiting c-kit kinase
TW200611693A (en) GPR35 and modulators thereof for the treatment of metabolic-related disorders
UA106082C2 (uk) АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
WO2003106656A3 (en) SINGLE-DOMAIN COMPOUNDS ASSOCIATED WITH TDF AND THE LIKE THEREOF